Soluble E‐cadherin promotes invasiveness of neoplastic cells in salivary gland carcinoma ex pleomorphic adenoma
- 5 December 2022
- journal article
- research article
- Published by Wiley in Journal of Oral Pathology & Medicine
- Vol. 52 (1) , 63-71
Abstract
Background: Soluble E-cadherin (sEcad), a tumor suppressor gene, has pro-oncogenic effects by binding to human epithelial growth factor receptor 2 (HER-2). In our previous study, 1/3 of carcinoma ex pleomorphic adenoma (CXPA) cases had HER-2 amplification, which is associated with tumorigenesis and malignancy. This study examines the role of sEcad in HER-2 amplified CXPA.Methods: Immunohistochemistry was used to examine E-cadherin (Ecad) expression in HER-2-amplified CXPA samples (n = 35). Western blot and ELISA were used to detect sEcad in two samples with Ecad and HER-2 overexpression and CXPA cell line. Lentivirus-mediated transfection was performed to knock down sEcad in CXPA cells. The cell proliferation, wound healing, and transwell assays were used to compare sEcad-knockdown cells with cells pretreated with recombinant human sEcad (rhEcad/Fc). sEcad and HER-2 interaction was determined through co-immunoprecipitation. RNA-sequencing, differential expression analysis, GO and KEGG analysis were used to identify sEcad-related signaling pathways and their protein phosphorylation levels were verified by western blotting.Results: Ecad was overexpressed in 77.1% of HER-2-positive CXPA, and sEcad was found in the CXPA cell line and two samples. sEcad promoted CXPA migration and invasion in vitro without sEcad and HER-2 interaction. sEcad-related differentially expressed genes were enriched in the IL-17, cAMP, and MAPK signaling pathways. Furthermore, sEcad activated the phosphorylation of Akt and MAPK/ERK signaling pathways.Conclusions: Most HER-2+ CXPAs express Ecad. sEcad could affect the invasiveness and migration of in vitro CXPA cells without HER-2. sEcad may be a therapeutic biomarker for CXPA patients.Keywords
Funding Information
- Natural Science Foundation of Shanghai Municipality (22ZR1437000)
This publication has 24 references indexed in Scilit:
- The predictive value of serum soluble E-cadherin levels in breast cancer patients undergoing preoperative systemic chemotherapyClinical Biochemistry, 2013
- Complete Response to Trastuzumab-Based Chemotherapy in a Patient with Human Epidermal Growth Factor Receptor-2-Positive Metastatic Salivary Duct Carcinoma ex Pleomorphic AdenomaCase Reports in Oncology, 2013
- Soluble‐E‐cadherin activates HER and IAP family members in HER2+ and TNBC human breast cancersMolecular Carcinogenesis, 2013
- Soluble E-cadherin: a critical oncogene modulating receptor tyrosine kinases, MAPK and PI3K/Akt/mTOR signalingOncogene, 2013
- HER‐2/neu gene amplification in carcinoma ex pleomorphic adenoma in relation to progression and prognosis: a chromogenic in‐situ hybridization studyHistopathology, 2012
- Activation of EGFR promotes squamous carcinoma SCC10A cell migration and invasion via inducing EMT‐like phenotype change and MMP‐9‐mediated degradation of E‐cadherinJournal of Cellular Biochemistry, 2011
- Establishment and characterization of pleomorphic adenoma cell systems: an in-vitro demonstration of carcinomas arising secondarily from adenomas in the salivary glandBMC Cancer, 2009
- The Ectodomain Shedding of E-cadherin by ADAM15 Supports ErbB Receptor ActivationJournal of Biological Chemistry, 2008
- The oncogene HER2: its signaling and transforming functions and its role in human cancer pathogenesisOncogene, 2007
- Carcinoma ex pleomorphic adenoma: A clinicopathologic reviewHead & Neck, 2001